Strategic investments included expanding the salesforce to 54 representatives, with a goal of reaching 57 by the end of Q3 FY2025. A new CRM system was initiated to enhance sales team productivity and ...
Stifel analysts maintained their Buy rating on Insmed shares (NASDAQ:INSM) and increased the price target from $88.00 to $97.00. According to InvestingPro data, the stock has delivered an impressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback